Neurocrine Biosciences — Feb 11, 2026 release

A reconciliation of GAAP to Non-GAAP financial results can be found in Table 3 and Table 4 at the end of this news release. Full-Year 2026 Financial Guidance Range (in millions) Low High INGREZZA Net Product Sales 1 $ 2,700  $ 2,800  GAAP R&D Expense 2 $ 1,200  $ 1,250  Non-GAAP R&D Expense 2, 3 $ 1,110  $ 1,160  GAAP and Non-GAAP IPR&D 4 $ 20  $ 20  GAAP SG&A Expense 5 $ 1,375  $ 1,400  Non-GAAP SG&A Expense 3, 5 $ 1,240  $ 1,265  1. INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington’s disease. 2. R&D guidance reflects the continued advancement of the Company’s pre-clinical and clinical portfolio including the Phase 3 programs for osavampator in MDD and direclidine in schizophrenia, and includes approximately $25 million of expense for development milestones related to our in-licensed product candidates. Development milestones are included in R&D guidance once achieved or deemed probable to achieve. 3. Non-GAAP guidance adjusted to exclude estimated non-cash stock-based compensation expense of approximately $90 million in R&D and $125 million in SG&A, divestiture-related expenses and vacated legacy campus facility costs. Non-cash stock-based compensation expense for performance-based equity awards is included in guidance once the predefined performance-based criteria for vesting is achieved or deemed probable to achieve. 4. IPR&D guidance represents completed collaboration and licensing arrangements. 5. SG&A guidance range reflects expense for o